[FGFR-targeted therapy in head and neck carcinomas].

CONCLUSION: Early clinical and preclinical data point to the promise of biomarker-directed treatment of patients with head and neck tumors using FGFR-targeted TKIs. PMID: 32519203 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research